Alex M. Nadzan

3.6k citations

68 papers · 2.9k indexed · 2 hit papers · h-index 26

Molecular Biology top 5%
Organic Chemistry top 5%
Genetics top 5%
Cellular and Molecular Neuroscience top 5%
Cancer Research top 5%

Co-authors: Marcus F. Boehm Richard A. Heyman Thomas Arrhenius Jie‐Fei Cheng Eric D. Bischoff G. Büchi John M. Essigmann William F. Busby
Topics: Neuropeptides and Animal Physiology (18 papers)Estrogen and related hormone effects (15 papers)Retinoids in leukemia and cellular processes (14 papers)
Cited by: Biochemistry Molecular Biology Cancer Research
Journals: Nature Proceedings of the National Academy of Sciences Journal of the American Chemical Society
Partner nations: United States United Kingdom Canada

In The Last Decade

Alex M. Nadzan

68 papers receiving 2.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Sensitization of diabetic and obese mice to insulin by retinoid X receptor agonists

1997 515 citations Ranjan Mukherjee, Peter J. Davies et al. Nature profile →
Structural identification of the major DNA adduct formed by aflatoxin B1 in vitro.

1977 389 citations Alex M. Nadzan et al. profile →

Peers

Countries citing papers authored by Alex M. Nadzan

Since Specialization

Citations

This map shows the geographic impact of Alex M. Nadzan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alex M. Nadzan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alex M. Nadzan more than expected).

Fields of papers citing papers by Alex M. Nadzan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alex M. Nadzan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alex M. Nadzan. The network helps show where Alex M. Nadzan may publish in the future.

Co-authorship network of co-authors of Alex M. Nadzan

This figure shows the co-authorship network connecting the top 25 collaborators of Alex M. Nadzan. A scholar is included among the top collaborators of Alex M. Nadzan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alex M. Nadzan. Alex M. Nadzan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Novel trifluoroacetophenone derivatives as malonyl-CoA decarboxylase inhibitors 2007 ·Bioorganic & Medicinal Chemistry Letters ·D. Michael A. Wallace,Masayuki Haramura,Jie‐Fei Cheng,Thomas Arrhenius,Alex M. Nadzan	8
2	Discovery of Potent and Orally Available Malonyl-CoA Decarboxylase Inhibitors as Cardioprotective Agents 2006 ·Journal of Medicinal Chemistry ·Jie‐Fei Cheng,Yujin Huang,(unknown),Masahiro Nishimoto,Larry Liu,Thomas Arrhenius,Guang Yang,E C O'Leary,Miguel Barbosa,Rick L. Barr,Jason R.B. Dyck,Gary D. Lopaschuk,Alex M. Nadzan	40
3	Aza-retinoids as novel retinoid X receptor-specific agonists 2005 ·Bioorganic & Medicinal Chemistry Letters ·Luc J. Farmer,(unknown),Stacie S. Canan Koch,C.‐K. HWANG,E. Adam Kallel,Lin Zhi,Alex M. Nadzan,(unknown),Youssef L. Bennani	13
4	Expression, purification, and characterization of human malonyl-CoA decarboxylase 2004 ·Protein Expression and Purification ·Demin Zhou,(unknown),(unknown),(unknown),(unknown),Steven J Brown,(unknown),M. R. PENA,(unknown),Jie‐Fei Cheng,Alex M. Nadzan,Miguel Barbosa,Jason R.B. Dyck,Gary D. Lopaschuk,Guang Yang	18
5	Discovery and structure–activity relationship of coumarin derivatives as TNF-α inhibitors 2004 ·Bioorganic & Medicinal Chemistry Letters ·Jie‐Fei Cheng,Mi Chen,David R. Wallace,(unknown),Thomas Arrhenius,Hirotaka Kashiwagi,Yoshiyuki Ono,Akira Ishikawa,Haruhiko Sato,(unknown),(unknown),Alex M. Nadzan	44
6	Novel nonsecosteroidal vitamin D mimics exert VDR-modulating activities with less calcium mobilization than 1,25-dihydroxyvitamin D3 1999 ·Chemistry & Biology ·Marcus F. Boehm,Patrick Fitzgerald,Aihua Zou,Marc Elgort,Eric D. Bischoff,(unknown),Dale E. Mais,Reid P. Bissonnette,R A Heyman,Alex M. Nadzan,Melvin Reichman,Elizabeth A. Allegretto	120
7	Sensitization of diabetic and obese mice to insulin by retinoid X receptor agonistsbreakdown → 1997 ·Nature ·Ranjan Mukherjee,Peter J. Davies,Diane L. Crombie,Eric D. Bischoff,Rosemary M. Cesario,Lily Jow,Lawrence G. Hamann,Marcus F. Boehm,C. E. Mondon,Alex M. Nadzan,James R. Paterniti,Richard A. Heyman	515
8	Activation of specific RXR heterodimers by an antagonist of RXR homodimers 1996 ·Nature ·Deepak S. Lala,Ranjan Mukherjee,Ira G. Schulman,Stacie S. Canan Koch,(unknown),Alex M. Nadzan,Glenn Croston,Ronald M. Evans,Richard A. Heyman	134
9	Synthesis of geometrically defined exocyclic olefins 1996 ·Tetrahedron Letters ·Youssef L. Bennani,C.‐K. HWANG,Stacie S. Canan Koch,(unknown),(unknown),(unknown),Alex M. Nadzan	2
10	The Intracellular Receptor and Signal Transducers and Activators of Transcription Factor Superfamilies: Novel Targets for Small-Molecule Drug Discovery 1995 ·Journal of Medicinal Chemistry ·Jon Rosen,Anthony J. Day,Todd K. Jones,E. Tracy Turner Jones,Alex M. Nadzan,Robert B. Stein	69
11	Amino acid-derived piperidides as novel CCKB ligands with anxiolytic-like properties 1995 ·Bioorganic & Medicinal Chemistry Letters ·Mark W. Holladay,Michael J. Bennett,(unknown),(unknown),James F. Kerwin,Michael A. Stashko,Thomas R. Miller,Alyssa B. O'Neill,Alex M. Nadzan,Jorge D. Brioni,Chun Wel Lin	5
12	DESIGN OF NOVEL RXR SELECTIVE RETINOIDS 1995 ·European Journal of Medicinal Chemistry ·Alex M. Nadzan,Marcus F. Boehm,Lin Zhang,(unknown),Lin Zhi,Steven K White,Dale E. Mais,E. Berger,Carla M. Suto,Michael McClurg,Peter J. Davies,Richard A. Heyman	5
13	Double bond isosteres of the peptide bond: Synthesis and biological activity of cholecystokinin (CCK) C-terminal hexapeptide analogs 1993 ·Bioorganic & Medicinal Chemistry ·Youe‐Kong Shue,Michael D. Tufano,George M. Carrera,Hana Kopecka,(unknown),Mark W. Holladay,Chun Wel Lin,David G. Witte,Thomas R. Miller,(unknown),Alex M. Nadzan	6
14	Characterization of the novel CCK analogs JMV-180, JMV-320, and JMV-332 in H345 cells 1992 ·Peptides ·David G. Witte,Alex M. Nadzan,Jean Martínez,Marc Rodriguez,Chun Wel Lin	13
15	Effects of selective CCK receptor agonists on food intake after central or peripheral administration in rats 1992 ·Brain Research ·Karen E. Asin,(unknown),Lisa Bednarz,Mark W. Holladay,Alex M. Nadzan	38
16	Development of potent and selective CCK-A receptor agonists from Boc-CCK-4: tetrapeptides containing Lys(N.epsilon.)-amide residues 1992 ·Journal of Medicinal Chemistry ·Kazumi Shiosaki,Chun Wel Lin,Hana Kopecka,(unknown),Bruce R. Bianchi,Thomas R. Miller,(unknown),Michael A. Stashko,Alex M. Nadzan	6
17	Evaluation of a stable CCK agonist (A68552) in conditioned avoidance responding in mice, rats, and primates: Comparison with typical and atypical antipsychotics 1992 ·Pharmacology Biochemistry and Behavior ·Donald R. Britton,Peter Curzon,(unknown),Michael Buckley,Michael D. Tufano,Alex M. Nadzan	10
18	Boc-CCK-4 derivatives containing side-chain ureas as potent and selective CCK-A receptor agonists 1991 ·Journal of Medicinal Chemistry ·Kazumi Shiosaki,(unknown),Hana Kopecka,Michael D. Tufano,(unknown),Thomas R. Miller,(unknown),Alex M. Nadzan	24
19	trans-3-n-propyl-L-proline is a highly favorable, conformationally restricted replacement for methionine in the C-terminal tetrapeptide of cholecystokinin. Stereoselective synthesis of 3-allyl- and 3-n-propyl-L-proline derivatives from 4-hydroxy-L-proline 1991 ·Journal of Medicinal Chemistry ·Mark W. Holladay,(unknown),(unknown),David S. Garvey,David G. Witte,Thomas R. Miller,(unknown),Alex M. Nadzan	53
20	Hybrid cholecystokinin (CCK) antagonists: new implications in the design and modification of CCK antagonists 1989 ·Journal of Medicinal Chemistry ·James F. Kerwin,Alex M. Nadzan,Hana Kopecka,Chun Wel Lin,Thomas R. Miller,David G. Witte,Stanley K. Burt	25

About Alex M. Nadzan

Alex M. Nadzan is a scholar working on Cellular and Molecular Neuroscience, Clinical Biochemistry and Biochemistry, having authored 68 papers that have together received 2.9k indexed citations. Recurring topics across this work include Neuropeptides and Animal Physiology (18 papers), Estrogen and related hormone effects (15 papers) and Retinoids in leukemia and cellular processes (14 papers). The work is most often cited by research in Biochemistry (223 citations), Molecular Biology (1.7k citations) and Cancer Research (355 citations). Alex M. Nadzan has collaborated with scholars based in United States, United Kingdom and Canada. Frequent co-authors include Marcus F. Boehm, Richard A. Heyman, Thomas Arrhenius, Jie‐Fei Cheng, Eric D. Bischoff, G. Büchi, John M. Essigmann, William F. Busby, Gerald N. Wogan and V N Reinhold. Their work appears in journals such as Nature, Proceedings of the National Academy of Sciences and Journal of the American Chemical Society.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact